According to one study, Lu and colleagues conducted the first-in-man clinical trial (NCT02793856) in patients with advanced non-small cell lung cancer (NSCLC) to assess the safety of a CRISPR/Cas9-mediated knockout of the PD-1 gene in autologous T lymphocytes [190]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.